St. Jude Medical touts clinical findings in support of its Genesis peripheral nerve stimulation implant in helping patients with chronic migraines.

Medical device giant St. Jude Medical (NYSE:STJ) announced new clinical results for its migraine-management implants, reporting significant relief for patients who, on average, spend more days with migraines than without.

At 12 weeks of follow-up, St. Jude provided pain relief in 42% of the patients, with 53% ranking that relief as "excellent" or "good," according to a press release.